

# Innovate UK

**Results of Competition: Establishing UK Treatment Centres for Advanced Therapies**

**Competition Code: 1709\_CRD\_HLS\_ATTTC**

**Total available funding is £30m**

**Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.**

<b>Participant organisation names</b>	<b>Project title</b>	<b>Proposed project costs</b>	<b>Proposed project grant</b>
<b>National Institute for Health Research Birmingham Biomedical Research Centre</b>	Midlands & Wales Advanced Therapy Treatment Centre (MW- ATTTC)	£2,331,750	£2,331,750
Asymptote Limited		£773,549	£386,750
Thermo Electron Limited		£325,663	£195,398
Trakcel Limited		£786,230	£550,361
Cellular Therapeutics Ltd		£847,386	£593,168
Rexgenero Limited		£537,328	£376,130
Velindre NHS Trust		£1,496,997	£1,466,407
NHS Blood and Transplant		£119,525	£119,525

World Courier Logistics (UK) Limited	£238,972	£119,486
Cell Medica Limited	£0	£0
Nottingham Uni Hospitals NHS Trust	£131,032	£131,032
Miltenyi Biotec Limited	£0	£0
Orbsen Therapeutics UK Ltd	£1,411,340	£987,938

**Project description - provided by applicants**

ATMPs, which can be cell or gene therapies, show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers.

ATMPs are just beginning to be available, with the UK playing a leading role. However, even when new ATMP therapies are developed and shown to be effective, there are major challenges in rolling them out to patients. The reasons for this include: complexities in transporting a 'living' product, and lack of familiarity with such products in most NHS hospitals.

The project lead is the Birmingham Biomedical Research Centre, a national centre of excellence. The Welsh government has also made a major investment in cell therapy and is supportive of NHS Wales as the joint-lead on this project. We are a team of industrialists, clinicians, academics and computer system experts who have all the necessary skills to succeed in this project.

Our group covers the Midlands and Wales giving us access to major teaching hospitals and almost 15 million people providing a unique opportunity to set cell therapy up to succeed.

We will:

- Set up a network of hospitals with medical staff trained to receive and administer ATMPs.
- Build seamless supply chains that ensure that 'living medicines' remain healthy and effective as they are moved from the production laboratory to the bedside.
- Put in place the IT systems to manage the end-to-end process.
- Validate this new infrastructure using real ATMPs
- Deliver a programme that uses this infrastructure to speed up the testing of ATMPs in clinical trials.
- Set-up protocols to test whether the cost of a new ATMP is justified by its clinical effectiveness.

The benefits of MW-ATTC are (a) Patients with challenging illnesses will get access to breakthrough medicines; (b) ATMP companies will get access to the clinical mainstream and market; (c) Investment in this important industry sector will increase, as we demonstrate that the UK is an excellent location for ATMP R&D. MW-ATTC will be one of three Advanced Therapy Treatment Centres in the UK, working together for patients and ATMP innovators, to reinforce the UK's position as a world leader in this important field.

**Note: you can see all Innovate UK-funded projects here**

<https://www.gov.uk/government/publications/innovate-uk-funded-projects> Use the Competition Code given above to search for this competition's results

# Innovate UK

**Results of Competition: Establishing UK Treatment Centres for Advanced Therapies**

**Competition Code: 1709\_CRD\_HLS\_ATT**

**Total available funding is £30m**

**Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.**

Participant organisation names	Project title	Proposed project costs	Proposed project grant
<b>The Newcastle upon Tyne Hospitals NHS Foundation Trust</b>	Northern Alliance Advanced Therapies Treatment Centre	£1,523,133.00	£1,523,133.00
Scottish National Blood Transfusion Service		£261,068.00	£261,068.00
NHS Lothian		£175,291.00	£175,291.00
NHS Greater Glasgow and Clyde		£175,251.00	£175,251.00
Edinburgh University		£250,606.00	£250,606.00
Datatrial Ltd		£284,192.00	£198,934.00
World Courier		£238,972.00	£119,486.00
Thermo Electron Ltd		£392,308.00	£235,385.00
Chiesi Ltd		£21,466.00	£0.00

Asymptote Ltd (part of GE Healthcare)	£987,110.00	£493,555.00
TrakCel Limited	£1,039,493.00	£727,645.00
Autolus Limited	£1,672,192.00	£1,003,315.00
NHS Blood and Transplant	£229,068.00	£229,068.00
Newcastle University	£663,749.00	£663,749.00
Roslin Cell Therapies Limited	£111,581.00	£78,107.00
Cell Medica Limited	£213,265.00	£127,959.00
Alcyomics Limited	£286,799.00	£200,759.00
Leeds Teaching Hospital NHS Trust	£410,923.00	£410,923.00
Miltenyi Biotec Limited	£0.00	£0.00
Academic Health Science Network for the North East and North Cumbria	£61,000.00	£42,700.00

### **Project description - provided by applicants**

The Northern Alliance Advanced Therapies Treatment Centre (NAATTC) is a group of NHS hospitals and services. NAATTC has a wide geographical reach across Scotland and the North of England and is responsible for the health care of 15 million NHS patients.

Advanced therapies are becoming increasingly available with a growing number of companies developing them both in the UK and worldwide. They are based on the administration of gene- and cell-based products in specialities such as haematology, autoimmunity, hepatology, cardiology and ophthalmology. They are thought to be more effective than existing treatments and provide treatments for diseases where currently no effective therapy exists. However most are still in clinical trials.

Advanced therapies present significant challenges to healthcare providers compared with existing treatments. Addressing these challenges in the NHS will require development and dissemination of new skills for nurses, doctors, hospital pharmacists, NHS managers, and commissioners such as NHS England and the clinical commissioning groups (CCGs). It will also require changes in the way treatment is delivered.

The changes required in the NHS can only be properly implemented through partnership with the companies that are developing and providing advanced therapies to the NHS. Manufacturers will need assistance with clinical trials to ensure optimal trial design, effective recruitment into clinical trials, and long term follow up of outcomes. The manufacturing and distributing processes are complex and it is critical that these systems are integrated effectively with those within the NHS.

The NAATTC already has considerable experience of delivering advanced therapies and clinical trials and will use this experience to work with manufacturers (and their supply chains) to significantly increase their capacity to deliver advanced therapies effectively, safely, and seamlessly to patients within the NHS. It will identify gaps in our existing provision and develop solutions to narrow and eliminate the gaps. It will share the best practice that it develops to other ATTCs and to other NHS organisations.

The outcomes will be to deliver these promising therapies to NHS patients and to make the NHS a global leader in their delivery, creating health and wealth for the UK.

**Note: you can see all Innovate UK-funded projects here**

<https://www.gov.uk/government/publications/innovate-uk-funded-projects> **Use the Competition Code given above to search for this competition's results**

# Innovate UK

**Results of Competition: Establishing UK Treatment Centres for Advanced Therapies**

**Competition Code: 1709\_CRD\_HLS\_ATT**

**Total available funding is £30m**

**Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.**

Participant organisation names	Project title	Proposed project costs	Proposed project grant
The Christie NHS Foundation Trust	A coordinated strategy to scale-up advanced therapies for patients in Manchester	£1,639,648.00	£1,639,648.00
Manchester University NHS Foundation Trust		£628,444.00	£628,444.00
Formedix Limited		£267,997.00	£187,598.00
Datatrial Ltd		£497,548.00	£348,284.00
Celluar Therapeutics Limited		£1,462,682.00	£1,023,877.00
Christie Pathology Partnership		£635,413.00	£381,247.00
Chaucer Group Limited		£85,560.00	£51,336.00
AstraZeneca plc		£90,000.00	£0.00
Asymptote Ltd		£1,249,828.00	£624,914.00
Agenus UK Ltd		£578,500.00	£404,950.00
University of Manchester		£1,163,194.00	£1,163,194.00
Aptus Clinical Limited		£661,711.00	£463,198.00

### **Project description - provided by applicants**

Advance Therapies are a new generation of treatments which use patients' cells as 'drug' to treat a variety of diseases. Although encouraging results have been reported, this technology is complex, expensive and currently only available to small numbers of patients.

We have formed the Innovate Manchester Advanced Therapy Centre Hub (iMATCH); this is a group of collaborators who share a vision of working more efficiently together so we can offer Advanced Therapies to more children and adult patients with cancer and non-cancer diseases.

iMATCH unites experts from The Christie NHS Foundation Trust and Manchester University NHS Foundation Trust, The University of Manchester and 9 businesses with specific expertise in different aspects of delivering Advanced Therapies. Our 9 commercial partners are; Cellular Therapeutics, Aptusclinical, Chaucer, Datatrial, Formedix, Asymptote, AstraZeneca, Agenus and The Christie Pathology Partnership.

iMATCH will resolve the challenges and expand facilities to allow us to design and run larger clinical trials so that we can to treat greater numbers of patients within the NHS, safely and efficiently.

We are going to focus on;

Coordinating patient cell collection

Processing and storage of those cells

Developing efficient systems to track samples from the patient, through manufacture and back to the patient

Ensure we have all the information we need, from each patient we treat, to know whether a clinical trial has been a success; this will include long term follow-up of patients

These clinical trials are complex and challenging to run; it is important that we provide specific education for our doctors, nurses and the teams that support them. We want to define the education packages needed then offer this training to all Manchester-based partners, then any national and international teams. This will increase the use of Advanced Therapies world-wide.

Manchester is an excellent choice for this investment by Innovate UK; we have a large population of 3.2 million people, two substantial hospital sites with existing experience offering these treatments to a variety of patients, a devolved Health Care System and an ability to draw together companies who can help us to overcome the complex challenges. Together we will improve patient outcomes.

**Note: you can see all Innovate UK-funded projects here**

<https://www.gov.uk/government/publications/innovate-uk-funded-projects> Use the Competition Code given above to search for this competition's results